Metalyse

Tenecteplase, the active ingredient in Metalyse, is a thrombolytic presented as a solution for injection for intravenous use. It is indicated for the rapid dissolution of fibrin clots in acute ST‑elevation myocardial infarction (STEMI) in adult patients, helping to restore coronary blood flow.

GNH USA supplies Metalyse as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance.

Metalyse (tenecteplase) is used in the management of acute coronary syndromes, specifically targeting thrombotic occlusion of coronary arteries.

Acute ST‑elevation myocardial infarction (STEMI): rapid fibrin clot dissolution to restore coronary perfusion. Acute myocardial infarction (non‑ST‑elevation): used off‑label in some regions to reduce infarct size. Coronary artery thrombosis: facilitates thrombus breakdown during emergency reperfusion therapy.

Common Side Effects: - Minor bleeding at injection site - Hypotension or transient blood pressure drop - Nausea or vomiting - Headache - Fever or chills - Dizziness or light‑headedness

Serious or Rare Side Effects: - Intracranial hemorrhage - Severe systemic bleeding (e.g., gastrointestinal, retroperitoneal) - Allergic reactions including anaphylaxis - Myocardial rupture - Severe hypotension requiring intervention - Hematuria or other organ‑specific bleeding events

Precautions for Metalyse include careful patient assessment and monitoring: - Bleeding risk assessment: evaluate recent surgery, trauma, or active bleeding. - Coagulation monitoring: check PT/INR and aPTT before and after administration. - Contraindications: avoid in patients with recent intracranial hemorrhage or stroke. - Caution in elderly patients and those with renal impairment. - Drug interactions: review concurrent anticoagulant or antiplatelet therapy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Metalyse may interact with several medication classes.

Major Interactions (Avoid): - Anticoagulants (e.g., heparin, warfarin) - Antiplatelet agents (e.g., aspirin, clopidogrel) - Other fibrinolytic agents (e.g., alteplase) - Direct thrombin inhibitors (e.g., dabigatran) - Factor Xa inhibitors (e.g., apixaban, rivaroxaban)

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs) - Selective serotonin reuptake inhibitors (SSRIs) - Glycoprotein IIb/IIIa inhibitors - ACE inhibitors or ARBs (potential additive hypotension) - Antihypertensive agents requiring dose adjustment